Saito Ryo, Yoshimura Kentaro, Shoda Katsutoshi, Furuya Shinji, Akaike Hidenori, Kawaguchi Yoshihiko, Murata Tasuku, Ogata Koretsugu, Iwano Tomohiko, Takeda Sen, Ichikawa Daisuke
First Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi 4093898, Japan.
Department of Anatomy and Cell Biology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi 4093898, Japan.
Oncol Lett. 2021 May;21(5):405. doi: 10.3892/ol.2021.12666. Epub 2021 Mar 22.
Biomarkers may be of value for the early detection of gastric cancer (GC) and the preoperative identification of tumor characteristics to guide treatment strategies. The present study analyzed the expression levels of phospholipids in plasma from patients with GC using liquid chromatography/electrospray ionization-mass spectrometry (LC/ESI-MS) to detect reliable biomarkers for GC. Furthermore, combining the results with a machine learning strategy, the present study attempted to establish a diagnostic system for GC. A total of 20 plasma samples from preoperative patients with GC and 16 plasma samples from tumor-free patients (controls) were selected from our biobank named 'SHINGEN (Yamanashi Biobank of Gastroenterological Cancers)', which includes a total of 1,592 plasma samples, and were analyzed by LC/ESI-MS. The obtained data were discriminated using a machine learning-based diagnostic algorithm, whose discriminant ability was confirmed through leave-one-out cross-validation. Using LC/ESI-MS, the levels of 236 lipid molecules were determined. Biomarker analysis revealed that a few lipids that were downregulated in the GC group could discriminate between the GC and control groups. Whole lipid composition analysis using partial least squares regression revealed good discrimination ability between the GC and control groups. Integrative analysis of all molecules using the aforementioned machine learning method exhibited a diagnostic accuracy of 94.4% (specificity, 93.8%; sensitivity, 95.0%). In conclusion, the outcomes of the present study suggested the potential future application of the aforementioned system in clinical settings. By accumulating more reliable data, the present system will be able to detect early-stage cancer and will be capable of predicting the efficacy of each therapeutic strategy.
生物标志物对于胃癌(GC)的早期检测以及术前肿瘤特征的识别以指导治疗策略可能具有重要价值。本研究使用液相色谱/电喷雾电离质谱法(LC/ESI-MS)分析了GC患者血浆中磷脂的表达水平,以检测GC的可靠生物标志物。此外,结合机器学习策略,本研究试图建立一种GC诊断系统。从我们名为“SHINGEN(山梨胃肠癌生物样本库)”的生物样本库中选取了20例GC术前患者的血浆样本和16例无肿瘤患者(对照组)的血浆样本,该生物样本库共包含1592份血浆样本,并通过LC/ESI-MS进行分析。使用基于机器学习的诊断算法对获得的数据进行判别,其判别能力通过留一法交叉验证得以确认。通过LC/ESI-MS测定了236种脂质分子的水平。生物标志物分析显示,GC组中下调的一些脂质能够区分GC组和对照组。使用偏最小二乘回归进行的全脂质成分分析显示GC组和对照组之间具有良好的判别能力。使用上述机器学习方法对所有分子进行综合分析,诊断准确率为94.4%(特异性为93.8%;敏感性为95.0%)。总之,本研究结果表明上述系统未来在临床环境中具有潜在应用价值。通过积累更多可靠数据,本系统将能够检测早期癌症,并能够预测每种治疗策略的疗效。